GSK Likes Its Go-It-Alone Strategy Over A Mega-Merger
This article was originally published in The Pink Sheet Daily
GlaxoSmithKline’s solo strategy is the right one, CEO Andrew Witty said, brushing aside questions about a potential merger with Pfizer during the company’s third quarter sales and earnings call.
You may also be interested in...
Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.
Company announces that Lp-PLA2 inhibitor darapladib fails Phase III STABILIITY outcomes study, the latest in a string of pharma CV failures.
Priya Singhal took over as Biogen's top R&D leader on an interim basis after Al Sandrock’s unexpected retirement. "I understand that this is a challenging time," she told Scrip.